VeraMorph & Dyad Medical

At our monthly breakfast meeting on January 11, 2022, Beacon Angels met in person and remotely to hear the following new company funding presentations:

  • VeraMorph: reformulating generic drugs to be more efficacious orally and co-developing new drugs through partnerships as a means to establish a diversified, low-risk portfolio of therapeutics across a wide range of disease areas; and
  • Dyad Medical: developing AI-enabled clinical applications to assist cardiologists in the interpretation of medical images.

We also considered a follow-on funding proposal from portfolio company GelMEDIX, which is developing a therapeutic, drug-eluting gel capsule for the eye.

We discussed the developing new funding round for

  • NF2 Therapeutics, which is developing a curative gene replacement therapy for the deafness, loss of mobility and devastating brain tumors caused by the rare disease NF2, and antibody-drug conjugates to treat NF2-caused meningiomas. Both therapies are eligible for the FDA’s Orphan Drug Designation.

Members will deliver due diligence reports as follows:

  • Shoreline Biome (Zainulbhai, Doscher & Smith) developing and selling patent-protected assays for more accurate and comprehensive human microbiome testing and research;
  • Jaia Robotics (Dave Smith) developing “JaiaBots,” low-cost, high-speed, micro-sized autonomous aquatic robots that work in pods of up to 20 to collect aquatic data from coastal waters up to 100m, estuaries, rivers, lakes and marshlands; and
  • Imago Rehab (Michael Pietrasiewicz, Vicky Davis), providing a virtual clinic using telerehab supplemented by a robotic glove to facilitate daily, high-repetition rehabilitation for hand-impaired stroke patients.

We also heard updates on Beacon’s portfolio companies

About Angel Treaty

Dedicated to fostering due diligence sharing between angel groups.
This entry was posted in Beacon Angels Events, Beacon Events, Boston angel investing, Funding Presentations, Uncategorized and tagged . Bookmark the permalink.